The Chinese State Food and Drug Administration (SFDA) has approved Victoza for the treatment of type 2 diabetes.
Diabetes is a rapidly growing disease in China, and Victoza offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents.
Novo Nordisk expects to launch Victoza in China in the second half of 2011.
